Abstract: The present invention provides new compounds displaying high affinity for adenosine A3 receptors. It also provides modulators of adenosine A3 receptors. It further provides compounds for the treatment and/or prophylaxis of conditions and diseases where adenosine A3 receptor plays a role. Pharmaceutical compositions for the treatment and/or prophylaxis of conditions and diseases where adenosine A3 receptors play a role are also described.

Abstract: The present invention relates to the use of substrates of an UDP-glucuronosyltransferase (UGT) and salts thereof, for the prevention and/or the treatment of neurological disorders. In preferred embodiment, the present invention relates to the use of substrates of at least an UDP-glucuronosyltransferase (UGT) expressed in brain and salts thereof, for the prevention and/or the treatment of neurological disorders. It further relates to the use of said substrates, and salts thereof, for preventing and/or treating glutamate cytotoxicity, and more specifically of glutamate induced neurological disorders. Additionally, it concerns the use of said substrates, and salts thereof, for making drugs exerting an inhibitory effect on the release of glutamate.